INDO US BIOTECH
Back to Income Statement
|
INDO US BIOTECH Last 5 Year Revenue History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹104 Cr | ₹73 Cr | ₹62 Cr | ₹50 Cr | ₹40 Cr |
What is the latest Revenue of INDO US BIOTECH ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹104 Cr |
| Mar2024 | ₹73 Cr |
| Mar2023 | ₹62 Cr |
| Mar2022 | ₹50 Cr |
| Mar2021 | ₹40 Cr |
How is Revenue of INDO US BIOTECH Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹104 Cr | 42.56 | |
| Mar2024 | ₹73 Cr | 17.96 | |
| Mar2023 | ₹62 Cr | 23.36 | |
| Mar2022 | ₹50 Cr | 24.86 | |
| Mar2021 | ₹40 Cr | - | |
Compare Revenue of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹217.7 Cr | 8.2% | -23% | -39.1% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,022.0 Cr | 4.4% | -12.6% | -20.4% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,365.9 Cr | 7.2% | 13.4% | -31.9% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,908.7 Cr | 11.6% | 4.1% | -22.5% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,053.5 Cr | 49% | 18.6% | -29.3% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹372.1 Cr | -3.4% | 12% | -19.2% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | 8.2% |
-23% |
-39.1% |
| SENSEX | -1.6% |
-8.8% |
-4.1% |
You may also like the below Video Courses